Stock DNA
Pharmaceuticals & Biotechnology
INR 2,184 Cr ()
139.00
36
0.00%
0.00
0.00%
4.50
Total Returns (Price + Dividend) 
Sai Parenteral's for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Announcement under Regulation 30 (LODR)-Press Release / Media Release
05-Oct-2026 | Source : BSEMedia release about the acquisition.
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
03-Oct-2026 | Source : BSEMonitoring agency report for the quarter ended 30 June 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
01-Oct-2026 | Source : BSEIntimation of Schedule of Analyst / Institutional Investor meetings under Regulation 30 (read with Para A of Part A of Schedule III) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.98%)
Held by 7 FIIs (4.03%)
Vijitha Gorrepati (28.91%)
Bhaskara Rao Bollineni (4.56%)
25.33%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is -7.06% vs 47.58% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is -10.75% vs 2,663.89% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 133.58% vs 6.08% in Mar 2025
YoY Growth in year ended Mar 2026 is -1.18% vs 71.38% in Mar 2025